PsyMed Ventures

General Partners and co-founders Matias Serebrinsky and Greg Kubin lead investment decisions. Serebrinsky brings experience running Nvidia Inception in North America and co-founding CookUnity, while Kubin previously co-founded a SaaS platform and personally invested in over 20 mental health companies. Dina Burkitbayeva, the third co-founder, focuses on portfolio operations as CEO of Freedom Biosciences. The firm's investment committee is supplemented by venture partners with technical neuroscience background.

PsyMed sources through a combination of academic neuroscience networks, operator referrals from its podcast 'Business Trip', and relationships with incubators and accelerators in the neurotech space. Venture Partner Tim Gardner, a founding Neuralink member, provides direct access to brain-computer interface and bioengineering talent. The firm's public content and newsletter platform serve as an inbound magnet for founders operating at the intersection of AI, digital health, and psychiatry.

The firm focuses primarily on early-stage and startup-stage companies. Its portfolio spans pre-clinical therapeutics, regulatory-stage digital health applications, and early neurotech hardware. PsyMed's positions are typically direct equity in emerging companies, consistent with a venture capital structure rather than a fund-of-funds model.

PsyMed concentrates on neuropsychiatry, neurodegeneration, and mental health broadly. This includes RNAi medicines (Aerska), non-hallucinogenic psychedelics (Delix Therapeutics), bioelectronic interventions (Motif Neurotech), and digital therapeutics for ADHD (Neurode). The firm also invests in peripheral modalities that affect brain health, such as metabolic psychiatry and holistic medicine.

The firm's website does not describe a formal syndicate structure, but its co-investor network is implied by the presence of venture partners and advisors from institutions like Yale School of Medicine, Rice University, Columbia University, and BridgeBio. PsyMed's portfolio companies typically include multiple VC participants in their cap tables, indicating standard syndication practices.

Business Trip is co-hosted by general partners Matias Serebrinsky and Greg Kubin. The podcast explores the future of mental health and wellness and operates as both a public education platform and a deal-flow engine. It reinforces PsyMed's positioning as a thematic investor by surfacing emerging research, products, and founders to a specialist audience.

The firm structures its team to include PhD-level computational neuroscientists, biotech investors with FDA-relevant experience, and patent attorneys. Venture Partner Negin Mokhtari was previously a partner at a biotech venture firm, and advisor Graham Pechenik is a registered patent attorney with biochemistry and cognitive neuroscience training. This composition suggests technical and regulatory risk is assessed within the partnership rather than outsourced.